Our Story

We provide personalized nutrition and actionable insights that allow you to live healthier and maintain normal blood sugar levels. Discover surprising food possibilities, while living your life with smarter nutritional and activity choices. We do this by studying your individual biometrics and lifestyle.

The product is based on a five year research conducted by Prof. Eran Segal and Prof. Eran Elinav from the Weizmann Institute of Science in Israel; the research was funded solely by the Weizmann Insitute of Science and upon its completion, the research technology was licensed to DayTwo. The research results were published in the journal Cell and the Research Video can be found here.

Our Team

Marius Nacht

Board Member, Co-Founder

Marius is chairman at Check Point Software (NASDAQ: CHKP), and has previously held various senior vice president roles. He is currently an angel investor, co-founder and board member of several IT and healthcare startups. Marius earned a B.Sc. in Physics and Mathematics from the Hebrew University of Jerusalem (Talpiot) and a M.Sc. in Electrical Engineering and Communication Systems from Tel Aviv University.)

Yuval Ofek

Chairman, Co-Founder

Yuval founded dbMotion Ltd., in 2004 and was its Chairman and CEO until acquired by Allscripts Healthcare, a leading US EMR company, in 2013. Prior to forming dbMotion, Yuval was involved in several startups in the Boston area and held various positions ranging from CTO, EVP and Chairman. Yuval was president of the Customer Experience Management division of Nice Systems and Vice President of

Enterprise Storage Development at EMC Corporation in Boston, Massachusetts. Yuval holds 82 U.S. and European patents in storage and networking. He has a bachelor’s degree in Electrical Engineering from the Technion – Israel Institute of Technology.

Lihi Segal

CEO, Co-Founder

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.

For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Zeev Zehavi

Zeev Zehavi is Vice President of Venture Investments for Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and joined in 1999. He is based out of offices in Israel and Belgium. Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd.

While operating this consultant business for medical device and pharmaceutical start-up companies, Mr. Zehavi initiated contacts with various Johnson & Johnson companies. Mr. Zehavi holds a Bachelor of Science from Hebrew University of Jerusalem and a Master of Business Administration in Marketing and Finance from Tel Aviv University. He is fluent in Hebrew, English, and Arabic.

Yair Schindel

Co-Founder & Managing Partner

Co-Founder & Managing Partner at aMoon Fund  since October 2016. aMoon is a $100M Healthcare & Life Science Investment Platform which is a partnership between Dr. Yair Schindel and Mr. Marius Nacht the Co-Founder and Chairman of the Israeli cyber security giant Check Point.

 Dr. Schindel was the Founding CEO of the Government’s National Digital Bureau “Digital Israel” and the first acting Chief Digital Officer of the State of Israel. Prior to Digital Israel Dr. Schindel was the CEO of Start-up Nation Central aimed at accelerating Israeli innovation and entrepreneurship through deeper connections and co-innovation between Israel and the world. Prior to that Dr. Schindel was an investor, board member or advisory board member in several successful healthcare start-ups in the fields of devices, mobile health and big-data & analytics including OmniGuide Inc. Zebra Med. Vision & Medisafe Prior to SNC Dr. Schindel was Co-founder & CEO of MAOZ, which focuses on developing senior leadership for the Israeli public & social sectors. Dr. Schindel earned his MBA from Harvard Business School in Boston, USA and his BSc and MD degrees from the Goldman Medical School, Ben-Gurion University in Beer-Sheba, Israel.

Eric de La Fortelle

Eric is a Venture Partner with Seventure Partners, a Paris-based venture capital investor investing broadly in life sciences (Rx, Dx, medical device) with a specific focus on the human microbiome. Seventure has raised the first fund worldwide dedicated to the microbiome, called Health for Life, in Dec 2015. Eric is a Board member of Mint Solutions BV, Maat Pharma SA, TargEDys SA and is an observer on the Boards of BiomX, DayTwo and Anaeropharma Science as a representative for Seventure.

Formerly, Eric was CEO of Delenex Therapeutics, a Zurich-based biotechnology company discovering and developing antibodies for topical application to the skin. Prior to that he led Roche’s global function of External Research and Technologies.Eric is a scientist by training, with contributions in the field of protein structure determination by X-ray crystallography. He was trained as an engineer and physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, a post-graduate diploma in biomedicine from IFSBM (Institut Gustave-Roussy), and an MBA (honors) from INSEAD.

Prof. Eran Elinav

Scientific Consultant, MD PhD

Eran is a Professor leading a research group at the Immunology Department of the Weizmann Institute of Science. His group focuses on deciphering the molecular basis of host-microbiome interactions and their effects on health and disease, with a goal of personalizing medicine and nutrition.
Prof. Elinav published over 110 publications, and received several awards for his work, including the 2013 Alon prize, and the 2015 Rappaport prize, awarded annually to one scientist for outstanding accomplishments in the field of biomedical research.

Before joining the Weizmann Institute, Prof. Elinav held an independent research position as a physician-Scientist at the Institute for Gastroenterology and Liver disease at the Tel Aviv Sourasky Medical Center. Prof. Elinav completed his medical doctor’s (MD) degree at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by a clinical internship, residency in internal medicine, and a clinical and research position at the Tel Aviv Medical Center Gastroenterology institute. He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine.

Prof. Eran Segal

Scientific Consultant, PhD

Eran is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His research focuses on studying the relationship between nutrition, health and gut microbes in human individuals.
Prof. Segal published over 110 publications, and received several awards and honors for his work, including the EMBO young investigator award, the Michael Bruno award, and the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in the field of computational biology. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.

Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York. Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a PhD. in Computer Science and Genetics in 2004, from Stanford University.

Yuval Ofek

Chairman, Co-Founder

Yuval founded dbMotion Ltd., in 2004 and was its Chairman and CEO until acquired by Allscripts Healthcare, a leading US EMR company, in 2013. Prior to forming dbMotion, Yuval was involved in several startups in the Boston area and held various positions ranging from CTO, EVP and Chairman. Yuval was president of the Customer Experience Management division of Nice Systems and Vice President of

Enterprise Storage Development at EMC Corporation in Boston, Massachusetts. Yuval holds 82 U.S. and European patents in storage and networking. He has a bachelor’s degree in Electrical Engineering from the Technion – Israel Institute of Technology.

Lihi Segal

CEO, Co-Founder

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.

For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Davidi Bachrach

COO

Davidi was the VP Product Management, Population Health in Allscripts where he managed the product life cycle from strategic planning and product roadmap to tactical activities, specifying and prioritizing market requirements for the Population Health products. Prior to Allscripts, he was the VP Professional Services for dbMotion Ltd., managed the company enterprise-wide projects in North America,

planning and implementation of dbMotion technologies at customer sites, developing product assimilation methodologies and providing the technical focal point for system integration, customer support and training. He has a BSc degree in Industrial Engineering and MBA degree from the Ben Gurion University in Israel

Josh Stevens

President

Over the past 25 years, Josh has operated and invested in both public and private growth companies in the CRM, EMR, and health benefits administration categories. Josh is an active advisor and investor in early-stage health companies that support outcomes-based-care in diagnostics, chronic-condition-management, and billing & reimbursement services.

Prior to DayTwo, Josh was CEO of Keas (acquired by Welltok), a healthcare SaaS company, that provided health benefits administration to employers and their employees. Prior to Keas, Josh was CRO for YouSendIt (Hightail) and prior to YouSendIt, Josh served and Chief Strategy & Revenue Officer for TicketsNow (acquired by Ticketmaster). Prior to working in early stage companies, Josh spent a decade at AOL where he was General Manager of eCommerce, after having served five years in Corporate Development. Josh started his career on Wall Street in corporate finance at the Chase Manhattan Bank.
In his free time, Josh serves on the Presbyterian Board of Pensions, and for 25 years Josh has also served as a coach for the Special Olympics

Amir Golan

CCO

Amir oversees DayTwo’s commercial activity in international markets.
Amir brings a wide range of leadership experience in building and managing commercial teams that drive rapid growth in international markets. Before Joining DayTwo, Amir served as Executive VP of Business Development at Signals Analytics, a technology-driven, Saas company that is funded by Sequoia Capital, where he played a key role penetrating US and European

markets, dramatically expanding the global customer base to over 50 Fortune 1000 companies.
Before joining Signals, Amir was a Co-Founder and Managing Partner at Arazim Agro, an Israeli agritech company. He served as an Intelligence Officer in the Israeli Air Force and as Assistant to the Israeli Defense Attache in Washington DC. Amir holds an MBA from Ben Gurion University.

Shahar Azulay

Head of Research

Shahar was a Senior Project Manager in Diskin Advanced Technologies where he led larger-scale Cyber security assessment project with Fortune-500 companies abroad. Prior to that, Shahar was a Branch Manager in the Prime Minister’s office Cyber division where he managed a group of security researchers and software developers responsible for the engineering of complex communication backbone projects.

Shahar was a part of the elite IDF program “Psagot” and he hold a B.Sc in Electrical Engineering and a B.Sc in Physics from the Technion – Israel Institute of Technology.

Lior Froimovich

VP of Research and Development

Lior was the VP of research and development at Mobli, where he managed the product development, quality, production health and scalability to produce and maintain several high scale social applications used by millions of users. Lior also led an agile process of building the architecture of big data social platforms, cloud based solutions, multi-platforms mobile and web technologies. Before that he was VP of research and development at Odysii producing

a large scale SAAS targeted suggestive selling platform using Real-time Transaction analysis. Lior holds a B.Sc in software engineering from the Technion – Israel Institute of Technology.

Prof. Ari Shamiss

Prof. Ari Shamiss is the CEO of Sheba General Hospital, a 1400 bed acute care medical center in Israel. Prof. Shamiss holds MD from the Technion Institute and MPA from Harvard University. He is certified in Internal Medicine, Hypertension and Healthcare Management and he is a Professor in Tel Aviv University on these disciplines with more than 60 published scientific papers.Prof. Shamiss was the Surgeon General for the Israel Air Force (Col. Ret.) and the Director of its Aeromedical Institute and he is a graduate in excellence of the US Navy Aerospace Medical Institute.Prof.

Shamiss is involved in numerous global business projects including healthcare technologies, healthcare management services and infrastructure, investment consultancy, Healthcare Information Technology, homeland security, and emergency preparedness. (Apr 2016)

Steven Schwartz

As Senior Vice President, Strategy and Corporate Development at Healthways [Nasdaq: HWAY], Steve is responsible for company strategy, management of emerging businesses, as well as growth via partnerships, and M & A. Steve has more than 25 years of experience in building high-growth companies in healthcare and information technology, joining Healthways from Silicon Valley’s 23andMe. As VP of Business Development and Strategy at 23andMe he was instrumental in accelerating the company’s business-to-business growth

strategy with life sciences companies, health systems, health plans, and retailers. Steve has been a leading innovator and evangelist in the application of information technology in healthcare; from the adoption of mobile technologies, medical records, and giving consumers access to their data; to the use of big data and genomics in drug development and clinical decision support. Prior to 23andMe, Mr. Schwartz was Senior Vice President of Business Development at Allscripts, where he helped lead the company’s dramatic growth for more than a decade, securing strategic partnerships with some of the world’s leading information technology and life sciences companies. Schwartz also spent more than 10 years at LabCorp, contributing to its emergence as the nation’s leading clinical laboratory companies.